chr7:140481402:C>G Detail (hg19) (BRAF)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr7:140,481,402-140,481,402 |
hg38 | chr7:140,781,602-140,781,602 View the variant detail on this assembly version. |
HGVS
Type | Transcript | Protein |
---|---|---|
RefSeq | NM_004333.4:c.1526G>C | NP_004324.2:p.Gly509Ala |
Ensemble | ENST00000288602.11:c.1526G>C | ENST00000288602.11:p.Gly509Ala |
ENST00000496384.7:c.1406G>C | ENST00000496384.7:p.Gly469Ala |
Summary
MGeND
Clinical significance |
![]() |
Variant entry | 15 |
GWAS entry | |
Disease area statistics | Show details |
Disease area statistics
MGeND
Clinical significance | Last evaluated | Condition | Origin | Submission ID | Submitter | Institute | Citation | Comment | Image |
---|---|---|---|---|---|---|---|---|---|
![]() |
caecum |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
colon, unspecified |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
malignant neoplasm of rectosigmoid junction |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
bronchus or lung, unspecified |
![]() |
MGS000041
(TMGS000094) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
caecum |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
malignant neoplasm of rectum |
![]() |
MGS000040
(TMGS000095) |
Hitoshi Nakagama | National Cancer Center Japan | ||||
![]() |
Primary adenocarcinoma of colon (disorder) |
![]() |
MGS000023
(TMGS000082) |
Manabu Muto | Kyoto University | ||||
![]() |
bronchus or lung, unspecified |
![]() |
MGS000042
(TMGS000093) |
Hitoshi Nakagama | National Cancer Center Japan |
ClinVar
Clinical significance | Last evaluated | Review status | Condition | Origin | Links |
---|---|---|---|---|---|
![]() |
2003-11-17 | no assertion criteria provided | non-Hodgkin lymphoma |
![]() |
Detail |
![]() |
2014-08-25 | criteria provided, single submitter | Non-small cell lung carcinoma |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | Neoplasm of the large intestine |
![]() |
Detail |
![]() |
2016-05-13 | no assertion criteria provided | Neoplasm |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided |
![]() |
Detail | |
![]() |
2016-05-31 | no assertion criteria provided | lung adenocarcinoma |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | Malignant melanoma of skin |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | Squamous cell lung carcinoma |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | prostate adenocarcinoma |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided |
![]() |
Detail | |
![]() |
2014-10-02 | no assertion criteria provided | lung carcinoma |
![]() |
Detail |
![]() |
2016-05-31 | no assertion criteria provided | multiple myeloma |
![]() |
Detail |
CIViC
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.242 | Lymphoma, Non-Hodgkin | NA | CLINVAR | Detail | |
0.567 | Cardio-facio-cutaneous syndrome | NA | CLINVAR | Detail | |
0.049 | Metastatic melanoma | Thus, the mutation BRAF G469A in MM might be related to a weak effectiveness of ... | BeFree | 26070258 | Detail |
0.015 | Malignant neoplasm of lung | The three most common BRAF mutations in lung cancers accounted for only 41% of t... | BeFree | 26386083 | Detail |
0.125 | Carcinoma of lung | The three most common BRAF mutations in lung cancers accounted for only 41% of t... | BeFree | 26386083 | Detail |
0.131 | Non-small cell lung carcinoma | NA | CLINVAR | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment... | CIViC Evidence | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Non-Hodgkin lymphoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Non-small cell lung carcinoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Neoplasm of the large intestine | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Neoplasm | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Squamous cell carcinoma of the skin | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Lung adenocarcinoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Malignant melanoma of skin | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Squamous cell lung carcinoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Prostate adenocarcinoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Transitional cell carcinoma of the bladder | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Lung carcinoma | ClinVar | Detail |
NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) AND Multiple myeloma | ClinVar | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Thus, the mutation BRAF G469A in MM might be related to a weak effectiveness of therapy with BRAF in... | DisGeNET | Detail |
The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mut... | DisGeNET | Detail |
The three most common BRAF mutations in lung cancers accounted for only 41% of the observed BRAF mut... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs121913355 dbSNP
- Genome
- hg19
- Position
- chr7:140,481,402-140,481,402
- Variant Type
- snv
- Reference Allele
- C
- Alternative Allele
- G
- Variant (CIViC) (CIViC Variant)
- G469A
- Transcript 1 (CIViC Variant)
- ENST00000288602.6
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/992
Genome browser